ArticleClinical Medicine Insights. Oncology2025
Predictive Value of Plasma Epstein-Barr Virus DNA Concentration for Recurrence and Metastasis in Advanced-Stage Nasopharyngeal Carcinoma: A Longitudinal, Descriptive Investigation.
Article in Clinical Medicine Insights. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities.British journal of biomedical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vietnam is an endemic region for nasopharyngeal cancer (NPC), with approximately 70% of cases diagnosed at stage III-IVa and 90% presenting with undifferentiated histology closely related to Epstein-Barr virus (EBV) infection. However, no studies have identified biomarkers predictive of recurrence and metastasis. This study aimed to determine the cut-off concentrations of cell-free (cf) EBV DNA for predicting recurrence and metastasis in NPC. Methods: A longitudinal descriptive study was conducted on 58 patients with stage III-IVa undifferentiated NPC between August 2021 and August 2024. We analysed the predictive value of cf EBV DNA concentrations at pre-treatment (preEBV) and post-treatment (postEBV, 6 months postEBV [EBV6], 12 months postEBV [EBV12]) in relation to disease progression and survival outcomes. Results: Of the 58 patients, 23 experienced recurrence and/or metastasis. The recurrence prediction cut-off concentration was 3980.0 copies/mL for preEBV (area under the curve [AUC] = 0.705, 95% confidence interval [CI]: 0.499-0.911, Se = 80.0%, Sp = 64.6%, odds ratio [OR] = 7.294, 95% CI: 1.389-38.307, accuracy [ACC] = 67.2%); 12.5 copies/mL for EBV6 (AUC = 0.783, 95% CI: 0.600-0.966, Se = 77.8%, Sp = 75.0%, OR = 10.5, 95% CI: 1.839-54.242, ACC = 75.5%); and 5.5 copies/mL for EBV12 (AUC = 0.766, 95% CI: 0.577-0.954, Se = 83.3%, Sp = 78.0%, OR = 17.778, 95% CI: 1.835-172.219, ACC = 78.7%). The metastasis prediction cut-off concentration for EBV12 was 42.5 copies/mL (AUC = 0.748, 95% CI: 0.502-0.994, Se = 66.7%, Sp = 80.5%, OR = 8.250, 95% CI: 1.278-52.254, ACC = 78.7%). Cut-off concentrations of preEBV, EBV6, and EBV12 were independent predictors of survival outcomes (except for EBV6). All results were statistically significant ( Conclusions: In advanced-stage NPC-undifferentiated subtype, preEBV, EBV6, and EBV12 serve as predictive biomarkers for recurrence and metastasis. Among these, EBV12 demonstrated the highest predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.